Seriously, how much longer before Nvidia (NASDAQ:NVDA) overtakes Microsoft (NASDAQ:MSFT) as the most valuable company in the world? The chipmaker just surpassed Saudi Aramco to become the third-most richly valued company at $2.2 trillion. With less than a trillion dollars to go to leapfrog over Microsoft, it’s really just a matter of time.But while Nvidia is sucking all the oxygen out of the room as it grows by leaps and bounds, there are other contenders for the trillion-dollar club. They might not reach i ...

Just when the weight-loss drug market was heating up, the temperature rose even more. Eli Lilly (LLY -1.85%) is already giving Novo Nordisk (NVO -2.58%) a run for its money with the approval in the fourth quarter of 2023 of Zepbound. Now another rival could be on the way.Viking Therapeutics (VKTX -3.77%) announced results last week from a phase 2 clinical study of VK2735 in helping patients lose weight. Its share price promptly skyrocketed more than 130%. Is Viking Therapeutics stock a better buy than Eli L ...

Two of the biggest names in the pharmaceutical industry right now are Eli Lilly (LLY -1.57%) and Novo Nordisk (NVO -1.55%). Each company is at the forefront of the red-hot weight-loss market due to their innovative roster of diabetes medications.Both companies develop glucagon-like peptide-1 (GLP-1) drugs, including Mounjaro, Ozempic, and Rybelsus. While these blockbuster drugs are not formally approved for chronic weight management by the Food and Drug Administration (FDA), losing weight can often be a byp ...

The gold rush for anti-obesity medicines is here, and the stakes are high. Per a report by Morgan Stanley Research, the market for weight loss drugs will be worth around $77 billion by 2030, despite being worth only $2.4 billion in 2022.Where should investors place their bets to gain some exposure to this hotter-than-hot trend? An investment in one of the established market leaders, like Eli Lilly (LLY 1.30%), could be sufficient -- but buying shares of an up-and-coming biotech like Viking Therapeutics (VKT ...

Eli Lilly (LLY) closed at $792.28 in the latest trading session, marking a +1.3% move from the prior day. This change outpaced the S&P 500's 0.12% loss on the day. On the other hand, the Dow registered a loss of 0.25%, and the technology-centric Nasdaq decreased by 0.41%.The drugmaker's shares have seen an increase of 17.15% over the last month, surpassing the Medical sector's gain of 3.58% and the S&P 500's gain of 4.83%.The investment community will be paying close attention to the earnings performance of ...

Novo Nordisk (NVO 3.72%) and Eli Lilly (LLY 3.77%) are two of the hottest pharmaceutical stocks of the past three years. Both companies have marked returns far in excess of the market's, thanks to popular demand for their freshly launched medications that treat obesity as well as type 2 diabetes. Both medicines are blockbuster drugs -- defined as those that generate annual sales totaling more than $1 billion. Blockbuster medicines tend to generate a lot of buzz, and the businesses that can get more drugs wi ...

Comparing Eli Lilly (LLY 3.77%) and Viking Therapeutics (VKTX 10.60%) might initially seem odd. The two drugmakers don't seem to have much in common. Eli Lilly is more than 50 times the size of Viking by market cap and boasts a long list of approved medicines and an impressive track record of success. Viking Therapeutics, on the other hand, is a clinical-stage, mid-cap biotech stock whose most advanced candidate isn't even in a late-stage study yet. Yet for invest purposes, is there any reason to choose Vik ...

You can find growth stocks in every sector. With healthcare making up nearly one-fifth of the U.S. economy, it's a great place to look.Three Motley Fool contributors have identified what they think are magnificent growth stocks to buy in March -- and all of them are in the healthcare sector. Here's why they picked Eli Lilly (LLY 3.77%), Moderna (MRNA 3.06%), and Vertex Pharmaceuticals (VRTX 2.86%).Eli Lilly can be a top growth stock for yearsDavid Jagielski (Eli Lilly): One stock that could potentially usur ...

As March 2024 draws near, the performance of the S&P 500 Index is starting to reveal itself, with some stocks demonstrating notable growth while others show potential for valuation increases in the months ahead.These stocks exhibit strong technical and fundamental indicators, complemented by the robust financials of their respective companies in sectors experiencing rapid growth.Finbold analyzed year-to-date performance, future potential, and recent financial results to identify the top performers within th ...

格隆汇2月28日｜礼来公司首席执行官David Ricks表示，预计最早将于明年在印度推出肥胖症药物tirzepatide。当被问及礼来是否愿意允许tirzepatide的授权仿制药上市时，Ricks称，只要对公司有意义，而且我们能供应市场，我们愿意接受任何能让更多患者受益的方式。该药物在美国的销售品牌为治疗糖尿病的Mounjaro和减肥药Zepbound。Ricks在印度举行的亚洲生物技术大会BioAsia上发表主旨演讲时说，印度应加强专利保护、废除多余的政策、建立社会安全网，以赢得全球制药商的更多投资。 (责任编辑：宋政 HN002) ...